- GW Home
- About GW
- University Life
- News & Events
- Faculty And Staff
Therapeutic Antibody to Eradicate Latent HIV-1 InfectionTechnology #016-021-nixon
Questions about this technology? Ask a Technology Manager
- Image Gallery
- Douglas F. Nixon
- Rui Andre Saraiva Raposo
- Miguel de Mulder Rougvie
- Dominic Paquin Proulx
- Phillip Brailey
- Vinicius D. Cabido
- Paul Zdinak
- Richard B. Jones
- Managed By
- Brian Coblitz Sr. Licensing Associate email@example.com (202) 994-4345
- Patent Protection
- Provisional Patent Application Filed
- IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis JCI Insight, Vol. 2 Issue 1; January 12, 2017
Fortunately, patients with human immunodeficiency virus (HIV-1) can now live a long life, but they must continually take the antiretroviral therapy that suppresses HIV-1 reproduction. If the virus could be fully eradicated from the patients, they could stop taking these expensive medications. The eradication of HIV-1 from patients remains unachievable due to the persistence of reservoirs of latent virus. GW researchers found that these reservoirs include CD4+ T-cells that contain low levels of replicating HIV-1 and overexpress Interferon Induced Transmembrane Protein 1 (IFITM1). Interferons are made by the host and suppress viral replication. Since this treatment targets a host factor it is not possible for HIV-1 to escape killing by mutating.
A mouse monoclonal antibody against IFITM1
induced significant killing of latently infected CD4+ cells through antibody-dependent
cell-mediated cytotoxicity (ADCC) in vitro (Fig. 1). Additional
development is needed to adapt the antibody for human use, and to evaluate
whether any other HIV reservoirs remain that do not express IFITM1 or are not
killed by the antibody.
A therapeutic treatment for HIV.
Kills efficiently and specifically latently infected cells.
Targets HIV-1 reservoir without the need for T-cell activation.
Targets host factors making it impossible for HIV-1 to escape by mutating.